Cargando…

The Cost Effectiveness of Patiromer for the Treatment of Hyperkalaemia in Patients with Chronic Kidney Disease with and without Heart Failure in Ireland

BACKGROUND AND OBJECTIVE: Hyperkalaemia can be a life-threatening condition, particularly in patients with advanced chronic kidney disease with and without heart failure. Renin-angiotensin-aldosterone system inhibitor therapy offers cardiorenal protection in chronic kidney disease and heart failure;...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ward, Thomas, Brown, Tray, Lewis, Ruth D., Kliess, Melodi Kosaner, de Arellano, Antonio Ramirez, Quinn, Carol M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9440184/ https://www.ncbi.nlm.nih.gov/pubmed/35925491 http://dx.doi.org/10.1007/s41669-022-00357-z

Ejemplares similares

A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure
por: Ward, Thomas, et al.
Publicado: (2023)

Patiromer sorbitex calcium for hyperkalaemia
Publicado: (2019)

Management of hyperkalaemia in acute kidney injury in a heart failure patient with patiromer
por: Slawik, Jonathan, et al.
Publicado: (2020)

Pharmacology of new treatments for hyperkalaemia: patiromer and sodium zirconium cyclosilicate
por: Rosano, Giuseppe M C, et al.
Publicado: (2019)

Experience with the potassium binder patiromer in hyperkalaemia management in heart failure patients in real life
por: Esteban‐Fernández, Alberto, et al.
Publicado: (2022)

Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease
por: Pitt, Bertram, et al.
Publicado: (2018)

Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial
por: Butler, Javed, et al.
Publicado: (2021)

The development of active middle ear implants: A historical perspective and clinical outcomes
por: Kließ, Melodi Koşaner, et al.
Publicado: (2018)

Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors
por: Pitt, Bertram, et al.
Publicado: (2015)

Evidence-based Clinical Decision Support Systems for the prediction and detection of three disease states in critical care: A systematic literature review
por: Medic, Goran, et al.
Publicado: (2019)

Patiromer utility as an adjunct treatment in patients needing urgent hyperkalaemia management (PLATINUM): design of a multicentre, randomised, double-blind, placebo-controlled, parallel-group study
por: Rafique, Zubaid, et al.
Publicado: (2023)

Hyperkalaemia in Heart Failure
por: Ismail, Umar, et al.
Publicado: (2021)

Comparing the Fiscal Consequences of Controlled and Uncontrolled Osteoarthritis Pain Applying a UK Public Economic Perspective
por: Martins, Rui, et al.
Publicado: (2021)

Patiromer utilization in patients with advanced chronic kidney disease under nephrology care in Germany
por: Pecoits-Filho, Roberto, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia
por: Bounthavong, Mark, et al.
Publicado: (2018)

Long‐term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin‐converting enzymes/angiotensin receptor blockers: results from AMETHYST‐DN
por: Pitt, Bertram, et al.
Publicado: (2018)

Prevalence, clinical impact and costs of hyperkalaemia: Special focus on heart failure
por: Maggioni, Aldo P., et al.
Publicado: (2021)

Hyperkalaemia in Heart Failure: Consequences for Outcome and Sequencing of Therapy
por: Murphy, Daniel, et al.
Publicado: (2022)

Hyperkalaemia management and related costs in chronic kidney disease patients with comorbidities in Spain
por: Olry de Labry Lima, Antonio, et al.
Publicado: (2021)

Case report: Patiromer-induced hypercalcemia
por: Wiederkehr, Michael R., et al.
Publicado: (2019)

How common is hyperkalaemia? A systematic review and meta-analysis of the prevalence and incidence of hyperkalaemia reported in observational studies
por: Humphrey, Toby, et al.
Publicado: (2021)

Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial( )
por: Butler, Javed, et al.
Publicado: (2022)

Can patiromer allow for intensified renin–angiotensin–aldosterone system blockade with losartan and spironolactone leading to decreased albuminuria in patients with chronic kidney disease, albuminuria and hyperkalaemia? An open-label randomised controlled trial: MorphCKD
por: Mårup, Frederik Husum, et al.
Publicado: (2022)

Management of hyperkalaemia in adults.
por: McVeigh, G.
Publicado: (2005)

Response to: Hyperkalaemia in heart failure: binding the patient to improved treatment?
por: Pitt, Bertram, et al.
Publicado: (2015)

A Rare Case of Patiromer Induced Hypercalcemia
por: Kanduri, Swetha Rani, et al.
Publicado: (2021)

The Role of Patiromer in Delaying the Onset of Renal Replacement Therapy in Patients with Advanced Renal Failure
por: Wadhwa, Nand K., et al.
Publicado: (2021)

Patiromer use in patients with heart failure: lessons and clinical considerations from the DIAMOND trial
por: Butler, Javed, et al.
Publicado: (2022)

Hyperkalaemia as a cause of undertreatment with mineralocorticoid receptor antagonists in heart failure
por: Henrysson, Josefin, et al.
Publicado: (2022)

Severe hyperkalaemia: demographics and outcome
por: Phillips, B.M., et al.
Publicado: (2014)

Surreptitious hyperkalaemia and its complications
por: Morgenstern, Tilo, et al.
Publicado: (2009)

Potassium homoeostasis and pathophysiology of hyperkalaemia
por: Kjeldsen, Keld Per, et al.
Publicado: (2019)

Nafamostat: Hyperkalaemia: case report
Publicado: (2021)

Evaluation of the Potential for Drug Interactions With Patiromer in Healthy Volunteers
por: Lesko, Lawrence J., et al.
Publicado: (2017)

Patiromer Acetate Induced Hypercalcemia: An Unreported Adverse Effect
por: Bhattarai, Shreeyukta, et al.
Publicado: (2019)

Patiromer and maintenance of RAASi therapy in hyperkalemic medicare patients
por: Desai, Nihar R., et al.
Publicado: (2019)

Assessment of Patiromer Monotherapy for Hyperkalemia in an Acute Care Setting
por: Di Palo, Katherine E., et al.
Publicado: (2022)

Effectiveness of patiromer in the treatment of hyperkalemia in chronic kidney disease patients with hypertension on diuretics
por: Weir, Matthew R., et al.
Publicado: (2017)

Letter to the editor regarding ‘‘Patiromer and Sodium Zirconium Cyclosilicate in Treatment of Hyperkalemia: A Systematic Review and Meta-analysis: Patiromer and Sodium Zirconium Cyclosilicate in Hyperkalemia’
por: Zarzuela, Donna, et al.
Publicado: (2021)

Hyperkalaemia: aetiology, epidemiology, and clinical significance
por: Tromp, Jasper, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1bakfsgh4mff7lfamic8lb64hr